Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07151417
PHASE2/PHASE3

Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.

Sponsor: Walter Reed National Military Medical Center

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury. The main questions it aims to answer are: Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)? Researchers will compare: Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function. (Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.) Participants will: Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint Be followed after surgery to measure: Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function

Official title: Adjunctive Use of Corticosteroid in Periarticular Injections in Primary Total Knee Arthroplasty

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2025-09-01

Completion Date

2026-08-31

Last Updated

2025-09-03

Healthy Volunteers

No

Interventions

DRUG

PAI

Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg

DRUG

PAI + steroid

Standard PAI + 40mg methylprednisolone (n = 40)

DRUG

PAI + zilretta

Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)

Locations (1)

Walter Reed National Military Medical Center

Bethesda, Maryland, United States